Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Careside

This article was originally published in The Gray Sheet

Executive Summary

Receives FDA market go-ahead for its Careside PT prothrombin time test to measure clot formation in citrated plasma. The test would be run on the Careside analyzer, slated for launch in the U.S. during the fourth quarter, which can provide chemistry, electrochemistry and coagulation test results. The device will be priced at just under $10,000
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel